{
    "clinical_study": {
        "@rank": "52226", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if a single dose of IL-10 compared to placebo is\n      safe and effective in reducing the incidence of post-ERCP acute pancreatitis for subjects\n      with increased risk."
        }, 
        "brief_title": "Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)", 
        "condition": [
            "Bile Duct Diseases", 
            "Biliary Tract Diseases", 
            "Gallbladder Diseases", 
            "Pancreatitis", 
            "Pancreatic Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bile Duct Diseases", 
                "Biliary Tract Diseases", 
                "Gallbladder Diseases", 
                "Pancreatic Diseases", 
                "Pancreatitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Adults weighing up to 125 kg who are undergoing ERCP for any of the following:\n\n          -  Evaluate recurrent abdominal pain;\n\n          -  Evaluate unexplained recurrent pancreatitis;\n\n          -  Evaluate prior post-ERCP pancreatitis;\n\n          -  Treatment of pancreatic disorders;\n\n          -  Treatment of Common Bile Duct Stones (without jaundice)\n\n        Exclusion criteria:\n\n          -  Active (acute) pancreatitis;\n\n          -  Chronic pancreatitis (moderate and severe cases);\n\n          -  ERCP to perform a second procedure on biliary tract;\n\n          -  Patients who previously had pancreatic sphincterotomy;\n\n          -  Known or suspected pancreatic cancer or cancer of Papilla of Vater;\n\n          -  Known or suspected other malignancy;\n\n          -  History of, or current clotting or bleeding problems;\n\n          -  Moderate and severe Anemia;\n\n          -  Low platelet counts"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "948", 
        "firstreceived_date": "June 20, 2002", 
        "id_info": {
            "nct_id": "NCT00040131", 
            "org_study_id": "P02580"
        }, 
        "intervention": {
            "intervention_name": "IL-10", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 21, 2013", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2003", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Belgium", 
                "Chile", 
                "France", 
                "Italy", 
                "United Kingdom"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040131"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }, 
    "geocoordinates": {}
}